Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 284, Issue 5 28-5, 2003, Pages

  Tarpey, Siobhán B ^a,b   Sawmiller, Darrell R ^a   Kelly, Claire ^a   Thompson, W Joseph ^a   Townsley, Mary I ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Capillary filtration coefficient; Permeability

Indexed keywords

2 DIETHYLAMINOETHANOL; ADENYLATE CYCLASE; CILOSTAMIDE; CYCLIC AMP; CYCLIC NUCLEOTIDE; FORSKOLIN; ISOENZYME; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; THAPSIGARGIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE PERMEABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; HEART FAILURE; HEART PACING; ISOLATED LUNG; LUNG HOMOGENATE; LUNG PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HYDROLYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT;

EID: 0037405613     PISSN: 10400605     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajplung.00373.2002     Document Type: Article

References (48)

1. Adamson RH, Liu B, Fry GN, Rubin LL, and Curry FE. Microvascular permeability and number of tight junctions are modulated by cAMP. Am J Physiol Heart Circ Physiol 274: H1885-H1894, 1998.
2. Ashikaga T, Strada SJ, and Thompson WJ. Altered expression of cyclic nucleotide phosphodiesterase isozymes during culture of aortic endothelial cells. Biochem Pharmacol 54: 1071-1079, 1997.
3. Barnard JW, Seibert AF, Prasad VR, Smart DA, Strada SJ, Taylor AE, and Thompson WJ. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor. J Appl Physiol 77: 774-781, 1994.
4. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75: 725-748, 1995.
5. Crapo JD, Barry BE, Behr P, Bachofen M, and Weibel ER. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 126: 332-337, 1982.
6. Draijer R, Atsma DE, van der Laarse A, and van Hinsbergh VW. cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 76: 199-208, 1995.
7. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG, and the Vesnarinone Study Group. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 329: 149-155, 1993.
8. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian MA, and Bristow MR. Pharmacologic and hemodynamic effects of combined β-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 108: 1524-1532, 1995.
9. Haynes J Jr, Killilea DW, Peterson PD, and Thompson WJ. Erythro-9-(2-hydroxy-3-nonyl) adenine inhibits cyclic-3′,5′-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung. J Pharmacol Exp Ther 276: 752-757, 1996.
10. He P, Zeng M, and Curry FE. Dominant role of cAMP in regulation of microvessel permeability. Am J Physiol Heart Circ Physiol 278: H1124-H1133, 2000.
11. Huang W, Kingsbury MP, Turner MA, Donnelly JL, Flores NA, and Sheridan DJ. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 49: 207-217, 2001.
12. 2+ signaling. Am J Physiol Heart Circ Physiol 275: H844-H851, 1998.
13. Ivey CL, Stephenson AH, and Townsley MI. Involvement of cytochrome P-450 enzyme activity in the control of microvascular permeability in canine lung. Am J Physiol Lung Cell Mol Physiol 275: L756-L763, 1998.
14. 2+ and permeability. Am J Physiol Lung Cell Mol Physiol 274: L810-L819, 1998.
15. Liu H and Maurice DH. Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br J Pharmacol 125: 1501-1510, 1998.
16. Lugnier C and Schini VB. Characterization of cyclic nucleotide phosphodiesterases from cultured bovine aortic endothelial cells. Biochem Pharmacol 39: 75-84, 1990.
17. Lugnier C, Stierle A, Beretz A, Schoeffter P, Lebec A, Wermuth CG, Cazenave JP, and Stoclet JC. Tissue and substrate specificity of inhibition by alkoxy-aryl-lactams of platelet and arterial smooth muscle cyclic nucleotide phosphodiesterases relationship to pharmacological activity. Biochem Biophys Res Commun 113: 954-959, 1983.
18. Manganiello VC, Murata T, Taira M, Belfrage P, and Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 322: 1-13, 1995.
19. Moore TM, Chetham PM, Kelly JJ, and Stevens T. Signal transduction and regulation of lung endothelial cell permeability. Interaction between calcium and cAMP. Am J Physiol Lung Cell Mol Physiol 275: L203-L222, 1998.
20. Muller MJ and Baer HP. Relaxant effects of forskolin in smooth muscle. Role of cyclic AMP. Naunyn Schmiedebergs Arch Pharmacol 322: 78-82, 1983.
21. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, and de Breyne B. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol 46: 191-196, 1994.
22. Packer M. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure. Am J Cardiol 63: 41A-45A, 1989.
23. Palmer D and Maurice DH. Dual expression and differential regulation of phosphodiesterase 3A and phosphodiesterase 3B in human vascular smooth muscle: implications for phosphodiesterase 3 inhibition in human cardiovascular tissues. Mol Pharmacol 58: 247-252, 2000.
24. Polson JB and Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36: 403-427, 1996.
25. Pyne NJ and Burns F. Lung phosphodiesterase isoenzymes. Agents Actions Suppl 43: 35-49, 1993.
26. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, and Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol Lung Cell Mol Physiol 266: L536-L543, 1994.
27. Reymann A, Braun W, and Woermann C. Response of rat small intestinal active aldohexose transport to elevation of mucosal cyclic AMP by forskolin and 3-isobutyl-1-methylxanthine in vitro. Naunyn Schmiedebergs Arch Pharmacol 331: 384-392, 1985.
28. Roy BJ, Pitts VH, and Townsley MI. Pulmonary vascular response to angiotensin II in canine pacing-induced heart failure. Am J Physiol Heart Circ Physiol 271: H222-H227, 1996.
29. Ruiz J, Shi QH, and Ho RJ. A dose-response study of forskolin, stimulatory hormone, and guanosine triphosphate analog on adenylate cyclase from several sources. Arch Biochem Biophys 251: 139-147, 1986.
30. Sato N, Asai K, Okumura S, Takagi G, Shannon RP, Fujita-Yamaguchi Y, Ishikawa Y, Vatner SF, and Vatner DE. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol Heart Circ Physiol 276: H1699-H1705, 1999.
31. Seeger W, Hansen T, Rossig R, Schmehl T, Schutte H, Kramer HJ, Walmrath D, Weissmann N, Grimminger F, and Suttorp N. Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability-effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Microvasc Res 50: 1-17, 1995.
32. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, and Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66: 241-277, 2001.
33. Smith CJ, He J, Ricketts SG, Ding JZ, Moggio RA, and Hintze TH. Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure. Cell Biochem Biophys 29: 67-88, 1998.
34. Smith CJ, Huang R, Sun D, Ricketts S, Hoegler C, Ding JZ, Moggio RA, and Hintze TH. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A. Circulation 96: 3116-3123, 1997.
35. Souness JE, Diocee BK, Martin W, and Moodie SA. Pig aortic endothelial-cell cyclic nucleotide phosphodiesterases. Use of phosphodiesterase inhibitors to evaluate their roles in regulating cyclic nucleotide levels in intact cells. Biochem J 266: 127-132, 1990.
36. Stevens T, Creighton J, and Thompson WJ. Control of cAMP in lung endothelial cell phenotypes. Implications for control of barrier function. Am J Physiol Lung Cell Mol Physiol 277: L119-L126, 1999.
37. Stevenson LW and Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261: 884-888, 1989.
38. Suttorp N, Ehreiser P, Hippenstiel S, Fuhrmann M, Krull M, Tenor H, and Schudt C. Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 174: 181-194, 1996.
39. Suttorp N, Hippenstiel S, Fuhrmann M, Krull M, and Podzuweit T. Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. Am J Physiol Cell Physiol 270: C778-C785, 1996.
40. Tanaka H, Tajimi K, and Kobayashi K. Milrinone improves arterial oxygenation in dogs with acute lung injury induced by oleic acid. J Cardiovasc Pharmacol 34: 806-810, 1999.
41. Tanaka H, Tajimi K, Matsumoto A, and Kobayashi K. Effects of milrinone on lung water content in dogs with acute pulmonary hypertension. J Pharmacol Toxicol Methods 28: 201-208, 1992.
42. Thomas RE, Armstrong DT, and Gilchrist RB. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Dev Biol 244: 215-225, 2002.
43. Thompson WJ, Ashikaga T, Kelly JJ, Liu L, Zhu B, Vemavarapu L, and Strada SJ. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4). Biochem Pharmacol 63: 797-807, 2002.
44. Thompson WJ, Terasaki WL, Epstein PM, and Strada SJ. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res 10: 69-92, 1979.
45. Townsley MI, Fu Z, Mathieu-Costello O, and West JB. Pulmonary microvascular permeability. Responses to high vascular pressure after induction of pacing-induced heart failure in dogs. Circ Res 77: 317-325, 1995.
46. c,i in lung and skeletal muscle. J Appl Physiol 61: 127-132, 1986.
47. 1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy. Mol Cell Biochem 205: 67-73, 2000.
48. Wright LC, Seybold J, Robichaud A, Adcock IM, and Barnes PJ. Phosphodiesterase expression in human epithelial cells. Am J Physiol Lung Cell Mol Physiol 275: L694-L700, 1998.